RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
23,94 $US
arrow_upward
+2,92%(+0,68) 1J
24,98 $US
arrow_upward
+4,35% (+1,04)bedtimeAprès clôture
Fermé : 29 mai, 16:00:01 UTC−4 · USD
search
Tous les symboles
1J
5J
1M
6M
Depuis début année
1AN
5ANS
MAX
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour RARE...
Ouverture
23,56 $US
Élevé
24,08 $US
Faible
23,30 $US
Cap. boursière
2,36 Md
Vol. moyen
1,63 M
Volume
1,84 M
+ haut sur 1 an
42,37 $US
+ bas sur 1 an
18,29 $US
BPA
-6,10 $US
Bêta
0,39
Actions en circulation
98,49 M
Nombre d'employés
1 k
Ouverture
23,56 $US
Élevé
24,08 $US
Faible
23,30 $US
Cap. boursière
2,36 Md
Vol. moyen
1,63 M
Volume
1,84 M
+ haut sur 1 an
42,37 $US
+ bas sur 1 an
18,29 $US
BPA
-6,10 $US
Bêta
0,39
Actions en circulation
98,49 M
Nombre d'employés
1 k
Articles
Provenant de diverses sources sur le Web
The Motley Fool
·
il y a 21 heures
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
The Legal Advocate
·
il y a 3 jours
RARE Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Development Continues - Book Value Growth
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
À propos de Ultragenyx Pharmaceutical Inc
PDGEmil Kakkis
Employés1,37 k
Date de création2010
Siège socialNovato, Californie, États-Unis
Secteur-
Site Webultragenyx.com
Les contenus générés par IA peuvent contenir des erreurs. En savoir plus